| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
| US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
Uceris is owned by Salix.
Uceris contains Budesonide.
Uceris has a total of 5 drug patents out of which 0 drug patents have expired.
Uceris was authorised for market use on 14 January, 2013.
Uceris is available in tablet, extended release;oral dosage forms.
Uceris can be used as induction of remission in patients with active, mild to moderate ulcerative colitis.
The generics of Uceris are possible to be released after 07 September, 2031.
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 14 January, 2013
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
UCERIS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic